Associated Papers
Stoichiometric transport of estrone 3-sulfate among genetic variants of OATP1A2 and OATP2B1 and structural analysis by molecular dynamics simulation: Impairment of gating mechanism in the unstable inward-open conformation of OATP2B1 (Asp215Val) significantly suppress the transport activity.
Akiyoshi T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
Mykkänen AJH et al.
Clinical Pharmacology and Therapeutics, 2024
Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism.
Penna GC et al.
Endocrine, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Thyroid Hormone Transporters in Pregnancy and Fetal Development.
Chen Z et al.
International Journal of Molecular Sciences, 2022
Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants.
Han H et al.
Drug Metabolism and Pharmacokinetics, 2022
Comparison of the inhibitory properties of the fruit component naringenin and its glycosides against OATP1A2 genetic variants.
Araki N et al.
Drug Metabolism and Pharmacokinetics, 2022
Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1.
Heaton BJ et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2022
Expression and Functional Contribution of Different Organic Cation Transporters to the Cellular Uptake of Doxorubicin into Human Breast Cancer and Cardiac Tissue.
Otter M et al.
International Journal of Molecular Sciences, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Sortica VA et al.
Pharmacogenomics, 2017
The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.
Costa ACC et al.
European Journal of Clinical Pharmacology, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH et al.
Molecular Pharmacology, 2017
Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.
Bexten M et al.
Molecular Pharmaceutics, 2015
Genetic polymorphisms and function of the organic anion-transporting polypeptide 1A2 and its clinical relevance in drug disposition.
Zhou Y et al.
Pharmacology, 2015
Somatic signature of brain-specific single nucleotide variations in sporadic Alzheimer's disease.
Parcerisas A et al.
Journal of Alzheimer's Disease : Jad, 2014
Primary and secondary thyroid hormone transporters.
Kinne A et al.
Thyroid Research, 2011
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
Yamakawa Y et al.
Clinical Pharmacology and Therapeutics, 2011
Environmental and genetic factors affecting transport of imatinib by OATP1A2.
Eechoute K et al.
Clinical Pharmacology and Therapeutics, 2011
Functional characterization of liver enhancers that regulate drug-associated transporters.
Kim MJ et al.
Clinical Pharmacology and Therapeutics, 2011
Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A et al.
Basic & Clinical Pharmacology & Toxicology, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R et al.
Pharmacogenetics and Genomics, 2010
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC et al.
Pharmacogenetics and Genomics, 2010
Pharmacogenetics of the organic anion transporting polypeptide 1A2.
Franke RM et al.
Pharmacogenomics, 2009
Ethnic differences in drug metabolism and toxicity from chemotherapy.
Phan VH et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
Badagnani I et al.
The Journal of Pharmacology and Experimental Therapeutics, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Membrane transporter proteins: a challenge for CNS drug development.
Girardin F
Dialogues in Clinical Neuroscience, 2006
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.
Lee W et al.
The Journal of Biological Chemistry, 2005